Wu Yi, Jia Xiaoying, Wu Namei, Zhang Xinghai, Wu Yan, Liu Yang, Zhou Minmin, Shen Yanqiong, Li Entao, Wang Wei, Lan Jiaming, Wang Yucai, Chiu Sandra
Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.
School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Acta Pharm Sin B. 2025 Feb;15(2):947-962. doi: 10.1016/j.apsb.2024.12.030. Epub 2024 Dec 30.
Booster vaccinations are highly recommended in combating the SARS-CoV-2 Omicron variant and its subvariants. However, the optimal booster vaccination strategies and related immune mechanisms with different prior vaccinations are under-revealed. In this study, we systematically evaluated the immune responses in mice and hamsters with different prime-boost regimens before their protective efficacies against Omicron were detected. We found that boosting with Ad5-nCoV, S-2P or S-6P induced significantly higher levels of neutralization activities against Omicron variants than CoronaVac and ZF2001 by eliciting stronger germinal center (GC) responses. Specifically, S-6P induced even stronger antibody responses against Omicron variants in CoronaVac and Ad5-nCoV-primed animals than non-Omicron-specific vaccines but with limited differences as compared to Ad5-nCoV and S-2P. In addition, boosting with a specific vaccine has the potential to remodel the existing immune profiles. These findings indicated that adenovirus-vectored vaccines and mRNA vaccines would be more effective than other types of vaccines as booster shots in combating Omicron infections. Moreover, the protective efficacies of the vaccines in booster vaccinations are highly related to GC reactions in secondary lymphatic organs. In summary, these findings provide timely important information on prime-boost regimens and future vaccine design.
强烈建议接种加强针以对抗新冠病毒奥密克戎变种及其亚变种。然而,针对不同既往接种情况的最佳加强针接种策略及相关免疫机制尚未完全明确。在本研究中,我们在检测小鼠和仓鼠针对奥密克戎的保护效力之前,系统评估了它们在不同初免 - 加强免疫方案下的免疫反应。我们发现,与科兴疫苗(CoronaVac)和重组蛋白疫苗(ZF2001)相比,用腺病毒载体新冠疫苗(Ad5 - nCoV)、S - 2P或S - 6P加强免疫可通过引发更强的生发中心(GC)反应,诱导出显著更高水平的针对奥密克戎变种的中和活性。具体而言,在科兴疫苗和腺病毒载体新冠疫苗初免的动物中,S - 6P诱导出的针对奥密克戎变种的抗体反应甚至比非奥密克戎特异性疫苗更强,但与腺病毒载体新冠疫苗和S - 2P相比差异有限。此外,用特定疫苗加强免疫有重塑现有免疫图谱的潜力。这些发现表明,在对抗奥密克戎感染时,腺病毒载体疫苗和mRNA疫苗作为加强针比其他类型的疫苗更有效。此外,疫苗在加强针接种中的保护效力与次级淋巴器官中的GC反应高度相关。总之,这些发现为初免 - 加强免疫方案及未来疫苗设计提供了及时且重要的信息。